Literature DB >> 17140356

Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors.

Aeron C Hurt1, Hui-Ting Ho, Ian Barr.   

Abstract

Development of effective drugs for the treatment or prevention of epidemic and pandemic influenza is important in order to reduce its impact. Adamantanes and neuraminidase inhibitors are two classes of anti-influenza drugs available for influenza therapy currently. However, emergence of resistance to these drugs has been detected, which raises concerns regarding their widespread use. In this review, resistance to the adamantanes and neuraminidase inhibitors will be discussed in relation to both epidemic and pandemic influenza viruses.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17140356     DOI： 10.1586/14787210.4.5.795

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN： 1478-7210            Impact factor:   5.091


  30 in total

1.  In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.

Authors:  Aeron C Hurt; Jessica K Holien; Ian G Barr
Journal:  Antimicrob Agents Chemother       Date:  2009-08-03       Impact factor: 5.191

2.  Oseltamivir resistance among influenza viruses: surveillance in northern Viet Nam, 2009-2012.

Authors:  Mai-Phuong Hoang Vu; Co Thach Nguyen; Le Khanh Hang Nguyen; Thi Kim Phuong Nguyen; Quynh Mai Le
Journal:  Western Pac Surveill Response J       Date:  2013-06-26

3.  Tracking oseltamivir-resistance in New Zealand influenza viruses during a medicine reclassification in 2007, a resistant-virus importation in 2008 and the 2009 pandemic.

Authors:  Richard J Hall; Matthew Peacey; Jacqui C Ralston; Danielle J de Joux; Judy Bocacao; Mackenzie Nicol; Molly Ziki; Wendy Gunn; Jing Wang; Q Sue Huang
Journal:  Western Pac Surveill Response J       Date:  2012-10-30

Review 4.  Pandemism of swine flu and its prospective drug therapy.

Authors:  R K Saxena; P Tripathi; G Rawat
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-08-16       Impact factor: 3.267

5.  Sequence analysis of the neuraminidase genes of avian influenza A viruses isolated from live bird markets in the United States.

Authors:  Yogesh Chander; Naresh Jindal; Srinand Sreevatsan; Sagar M Goyal
Journal:  Virus Genes       Date:  2011-04-20       Impact factor: 2.332

6.  Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza A virus experimental infection.

Authors:  Giorgio Conti; Walter Magliani; Stefania Conti; Lucia Nencioni; Rossella Sgarbanti; Anna Teresa Palamara; Luciano Polonelli
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

7.  Full genome comparison and characterization of avian H10 viruses with different pathogenicity in Mink (Mustela vison) reveals genetic and functional differences in the non-structural gene.

Authors:  Siamak Zohari; Giorgi Metreveli; István Kiss; Sándor Belák; Mikael Berg
Journal:  Virol J       Date:  2010-06-30       Impact factor: 4.099

8.  Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses.

Authors:  Aeron C Hurt; Jessica K Holien; Michael W Parker; Ian G Barr
Journal:  Drugs       Date:  2009       Impact factor: 9.546

9.  Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1).

Authors:  Nadezhda E Yun; Nathaniel S Linde; Michele A Zacks; Ian G Barr; Aeron C Hurt; Jeanon N Smith; Natallia Dziuba; Michael R Holbrook; Lifang Zhang; John M Kilpatrick; C Shane Arnold; Slobodan Paessler
Journal:  Virology       Date:  2008-01-29       Impact factor: 3.616

Review 10.  Genetic strategy to prevent influenza virus infections in animals.

Authors:  Jianzhu Chen; Steve C-Y Chen; Patrick Stern; Benjamin B Scott; Carlos Lois
Journal:  J Infect Dis       Date:  2008-02-15       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.